Your browser is no longer supported. Please, upgrade your browser.
BNTC Benitec Biopharma Limited weekly Stock Chart
BNTC [NASD]
Benitec Biopharma Limited
Index- P/E- EPS (ttm)-0.82 Insider Own- Shs Outstand1.57M Perf Week-5.76%
Market Cap7.28M Forward P/E- EPS next Y- Insider Trans- Shs Float1.22M Perf Month4.03%
Income- PEG- EPS next Q- Inst Own17.21% Short Float0.39% Perf Quarter-28.46%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.25 Perf Half Y-31.52%
Book/sh1.08 P/B4.31 EPS next Y- ROA- Target Price14.00 Perf Year-61.89%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range4.13 - 24.00 Perf YTD-8.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-80.62% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low12.59% ATR0.45
Employees- Current Ratio- Sales Q/Q-24.70% Oper. Margin- RSI (14)42.91 Volatility9.33% 9.35%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.54 Prev Close4.84
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume18.79K Price4.65
Recom- SMA20-3.33% SMA50-11.65% SMA200-50.84% Volume10,230 Change-3.93%
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Nov-27-19 08:00AM  ASX/NASDAQ ANNOUNCEMENT: Re-domiciliation to the United States PR Newswire -10.17%
Nov-17-19 07:02PM  Some Benitec Biopharma (ASX:BLT) Shareholders Have Taken A Painful 93% Share Price Drop Simply Wall St.
Nov-15-19 07:00AM  Public consultation launched on global tailings dam standards Reuters
Oct-31-19 08:30AM  Appendix 4C: Quarterly Cash Flow Report PR Newswire
Sep-30-19 09:24AM  Benitec Biopharma Limited Announces US$2.25 Million Registered Direct Offering PR Newswire -15.24%
Sep-19-19 09:15AM  Benitec Biopharma to present at Ladenburg Thalmann 2019 Healthcare Conference PR Newswire -15.85%
Sep-16-19 08:00AM  Benitec Biopharma Provides Update on BB-301 Oculopharyngeal Muscular Dystrophy (OPMD) Program PR Newswire
Sep-15-19 09:49PM  Does Market Volatility Impact Benitec Biopharma Limited's (ASX:BLT) Share Price? Simply Wall St.
Jul-31-19 08:30AM  ASX/NASDAQ ANNOUNCEMENT Appendix 4C: Quarterly Cash Flow Report PR Newswire +28.79%
Jul-11-19 11:34PM  Could The Benitec Biopharma Limited (ASX:BLT) Ownership Structure Tell Us Something Useful? Simply Wall St.
Jun-06-19 08:09AM  Update on Oculopharyngeal Muscular Dystrophy Program PR Newswire -34.18%
May-08-19 08:01PM  Should Benitec Biopharma Limited (ASX:BLT) Be Your Next Stock Pick? Simply Wall St.
Mar-06-19 09:52PM  Introducing Benitec Biopharma, The Stock That Tanked 92% Simply Wall St.
Jan-29-19 09:46PM  Have Insiders Been Buying Benitec Biopharma Limited (ASX:BLT) Shares This Year? Simply Wall St.
Dec-21-18 10:10AM  Benitec Provides Update on BB-401 Cancer Treatment Program PR Newswire -20.82%
Nov-23-18 12:01AM  Is Benitec Biopharma Limiteds (ASX:BLT) Balance Sheet A Threat To Its Future? Simply Wall St.
Nov-15-18 07:35AM  Detailed Research: Economic Perspectives on Knight-Swift Transportation, Benitec Biopharma, Eastern, Kiniksa Pharmaceuticals, Qualstar, and Nomura Holdings Inc ADR What Drives Growth in Today's Competitive Landscape GlobeNewswire +7.01%
Sep-19-18 08:00AM  Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor PR Newswire
Jul-14-18 02:02PM  3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jul-10-18 05:15PM  Axovant, Benitec Gain on Licensing Deal for Gene Therapy Zacks
08:10AM  Today's Research Reports on Stocks to Watch: Benitec Biopharma and Pfizer ACCESSWIRE
07:30AM  New Catalysts Could Send This $3 Medical Device Stock to $9 ACCESSWIRE
Jul-09-18 11:04AM  Axovant, Benetic Jump on Agreement to Develop Gene Therapy for MD TheStreet.com +51.93%
Jul-08-18 08:59PM  Benitec Announces Global Licensing Agreement for BB-301 for Treatment of Oculopharyngeal Muscular Dystrophy and Broad Platform Collaboration with Axovant PR Newswire
May-31-18 08:00AM  Benitec Biopharma reports financial results for the 2018 fiscal third quarter and provides operational update PR Newswire
May-15-18 08:00AM  Benitec to present OPMD data at the American Society of Gene and Cell Therapy Meeting PR Newswire
May-03-18 08:00AM  Benitec to Host Investor Webinar on the Company's Oculopharyngeal Muscular Dystrophy (OPMD) Program PR Newswire
Apr-24-18 08:00AM  ASX/NASDAQ Announcement PR Newswire
Mar-05-18 08:00AM  Benitec Biopharma Launches its Phase 2 Oncology Study in Australia PR Newswire
Feb-22-18 08:30AM  Benitec Biopharma reports financial results for the 2018 fiscal second quarter and provides operational update PR Newswire
Jan-23-18 04:17PM  Federal R&D Tax Credit Received PR Newswire
Jan-16-18 08:00AM  Benitec receives U.S. Orphan Drug Designation for BB-301, its ddRNAi therapeutic for the treatment of oculopharyngeal muscular dystrophy PR Newswire +9.06%
Nov-27-17 09:30AM  Alkermes Jumps on License Deal With Biogen -- Biotech Movers TheStreet.com
08:00AM  Benitec Biopharma provides update on OPMD orphan disease program PR Newswire
Oct-18-17 07:45AM  U.S. patent granted for Benitec hepatitis B program PR Newswire
Sep-05-17 02:54PM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended June 30, 2017 : September 5, 2017 Capital Cube
Sep-01-17 04:00PM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2017 By the Numbers : September 1, 2017 Capital Cube
Aug-08-17 08:30AM  Benitec Biopharma advances OPMD orphan disease program PR Newswire
Apr-05-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals Accesswire
07:30AM  Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals
Apr-04-17 04:40PM  Rising Biotechs: Paratek Among Stocks Surging On Trial Results Investor's Business Daily
04:40PM  Rising Biotechs: Paratek Among Stocks Surging On Trial Results
11:54AM  Here's Why Benitec Biopharma Stock Soared 79.7% Higher This Morning Motley Fool
08:00AM  Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications PR Newswire
08:00AM  Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
Mar-27-17 09:30AM  Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics Accesswire
Mar-13-17 06:00AM  Benitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million PR Newswire
Feb-16-17 08:00AM  Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China PR Newswire
Feb-03-17 09:45AM  M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix Accesswire
Feb-02-17 12:05PM  Why Benitec More Than Doubled 24/7 Wall St.
12:05PM  Why Benitec More Than Doubled
07:00AM  Benitec Biopharma makes significant progress in ocular program PR Newswire
Jan-30-17 08:00AM  Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital PR Newswire
Jan-18-17 09:30AM  Biotech Industry Outperforming Markets in 2017: Latest Reports on Benitec Biopharma and Tandem Diabetes Care Accesswire
08:26AM  Benitec Stock Up on Orphan Drug Status for BB-301 in EU Zacks
08:15AM  Blog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy Accesswire
Jan-17-17 11:05AM  Tuesdays Top Biopharma Movers 24/7 Wall St.
05:00AM  Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy PR Newswire
Dec-23-16 06:00AM  Benitec in-licenses clinical program for head and neck cancer from NantWorks PR Newswire
Dec-20-16 07:00AM  Benitec releases pivotal data in an in vivo hepatitis B model PR Newswire
Oct-24-16 07:10PM  Benitec initiates a strategic engagement with NantVentures Other
Sep-23-16 11:34AM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2016 By the Numbers : September 23, 2016
Aug-10-16 05:00AM  Benitec announces restructuring of Senior Executive team PR Newswire
May-24-16 04:45AM  Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016 PR Newswire
May-17-16 05:00AM  Benitec Biopharma to Host Corporate Update Conference Call PR Newswire
Apr-25-16 08:30AM  Benitec to present at the ASGCT 2016 Annual Meeting PR Newswire
Mar-08-16 08:16AM  Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo PR Newswire
Mar-07-16 02:29PM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended December 31, 2015
Feb-26-16 07:26AM  Benitec Biopharma downgraded by Maxim Group
Feb-25-16 10:13PM  Benitec Biopharma Limited: Interim Report for the Half Year Ended December 31, 2015 PR Newswire
06:42PM  Update on TT-034 Hepatitis C Clinical Trial PR Newswire
Jan-29-16 07:36PM  Appendix 4C - quarterly Other
Dec-10-15 07:51PM  Benitec Biopharma to Host Corporate Update Conference Call PR Newswire
Dec-08-15 05:05PM  Greg West, Benitec's Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer PR Newswire
01:18PM  BENITEC BIOPHARMA LTD/ADR Financials
Dec-07-15 08:00AM  Benitec's Hepatitis B Therapeutic Shows Positive Preclinical Results PR Newswire
Oct-29-15 11:13AM  Why the Australian Dollar Fell on Weak Inflation
Oct-22-15 08:00AM  Benitec Biopharma's Abstract Accepted for Presentation at the AASLD Liver Meeting 2015 PR Newswire
Oct-19-15 07:30AM  Benitec Forms Hepatology Clinical Advisory Board Other
Oct-14-15 08:00AM  Benitec Biopharma to Present at The 14th Annual BIO Investor Forum Other
Oct-07-15 07:00AM  Lonza and Benitec Enter Agreement to Develop Scalable AAV Manufacturing Process for ddRNAi Therapeutics PR Newswire
Sep-25-15 10:23AM  Benitec Biopharma rings Nasdaq opening bell at CNBC
Sep-24-15 10:00AM  Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Sep-23-15 08:00AM  Benitec Featured at CHI's "Discovery On Target" Conference PR Newswire
Sep-16-15 07:30AM  Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial PR Newswire
Aug-24-15 07:30AM  Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ PR Newswire
Aug-05-15 02:45PM  IPO Outlook: Planet Fitness Bargain Gym Memberships Growing Strong
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. The company was founded in 1995 and is headquartered in Melbourne, Australia.